You are here

Our science / Clinical Trials / Find a Trial / NCT02546375

A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands

Back to Search Print Save as PDF Bookmark Trial

NCT02546375

Last updated on December 18, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Royal Liverpool Hospital
Liverpool, Merseyside, L7 8XP United Kingdom
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Chronic Myeloid Leukaemia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0 +
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Diagnosis of Ph+ CML aged ≥18 years at bosutinib initiation.

- Prescribed bosutinib (irrespective of the phase of their disease) EITHER in normal
clinical practice since it received marketing authorisation (27th March 2013) by the
EMA11 OR via the compassionate use programme prior to marketing authorization.

- Where required, evidence of a personally signed and dated informed consent document
indicating that the patient (or a legally acceptable representative) has been informed
of all pertinent aspects of the study.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Prescribed bosutinib as part of an interventional clinical trial programme.

- Initiated on bosutinib less than 3 months prior to data collection taking place.

NCT02546375
Pfizer
Completed
A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Chronic Myeloid Leukaemia
A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands
NCT02546375
All Genders
0+
Years
Multiple Sites
Myelodysplastic Syndrome, Acute Myeloid Leukemia
A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML Patients
NCT02367456
All Genders
18+
Years
Multiple Sites
Myeloid Leukemia
A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid Leukemia
NCT03416179
All Genders
18+
Years
Multiple Sites
Healthy, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis
Study Of PF-06817024 In Healthy Subjects, In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis
NCT02743871
All Genders
18+
Years
Multiple Sites
A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands
A Retrospective Observational Research Study To Describe The Real World Use Of Bosutinib In The Uk And Netherlands
The purpose of this study is to describe the efficacy and safety of bosutinib in patients with chronic myeloid leukaemia used in a real world setting
Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample
CML out-patient clinics
Chronic Myeloid Leukaemia
Drug: Bosutinib
Bosutinib 100mg film-coated tablets; Bosutinib 500mg film-coated tablets Dosage as prescribed at treating institution; (observational study)
Other Name: Bosulif
Chronic Myeloid Leukaemia
Patients diagnosed with chronic myeloid leukaemia treated with Bosutinib
Intervention: Drug: Bosutinib
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
86
January 2017
January 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of Ph+ CML aged ?18 years at bosutinib initiation.
  • Prescribed bosutinib (irrespective of the phase of their disease) EITHER in normal clinical practice since it received marketing authorisation (27th March 2013) by the EMA11 OR via the compassionate use programme prior to marketing authorization.
  • Where required, evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.

Exclusion Criteria:

  • Prescribed bosutinib as part of an interventional clinical trial programme.
  • Initiated on bosutinib less than 3 months prior to data collection taking place.
Sexes Eligible for Study: All
18 Years to 99 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
 
NCT02546375
B1871052
No
Not Provided
Not Provided
Pfizer
Pfizer
pH Associates
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
March 2017

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now